Gradient Investments LLC reduced its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 8.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,522 shares of the company’s stock after selling 2,207 shares during the quarter. Gradient Investments LLC’s holdings in Novo Nordisk A/S were worth $1,477,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Winthrop Partners WNY LLC purchased a new stake in Novo Nordisk A/S during the third quarter worth approximately $28,000. Prime Capital Investment Advisors LLC acquired a new position in shares of Novo Nordisk A/S during the third quarter worth $28,000. Simon Quick Advisors LLC lifted its position in shares of Novo Nordisk A/S by 748.6% during the fourth quarter. Simon Quick Advisors LLC now owns 925 shares of the company’s stock worth $54,000 after purchasing an additional 816 shares in the last quarter. Doyle Wealth Management acquired a new position in shares of Novo Nordisk A/S during the second quarter worth $57,000. Finally, Pinnacle Bank lifted its position in shares of Novo Nordisk A/S by 21.7% during the third quarter. Pinnacle Bank now owns 1,140 shares of the company’s stock worth $59,000 after purchasing an additional 203 shares in the last quarter. Institutional investors own 7.26% of the company’s stock.
A number of research analysts have recently commented on the stock. ValuEngine cut shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research report on Tuesday. UBS Group cut shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Monday, November 18th. Barclays raised shares of Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, November 27th. Guggenheim cut shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Friday, January 3rd. Finally, Pareto Securities cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the company. Novo Nordisk A/S currently has a consensus rating of “Hold” and an average target price of $159.65.
Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Friday, November 1st. The company reported $0.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.02. The company had revenue of $4.51 billion for the quarter, compared to analysts’ expectations of $4.55 billion. Novo Nordisk A/S had a net margin of 32.44% and a return on equity of 75.48%. Sell-side analysts expect that Novo Nordisk A/S will post 2.45 EPS for the current fiscal year.
Novo Nordisk A/S Profile
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
Featured Story: Price to Earnings Ratio (PE) Basics
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.